## **Claris Lifesciences Limited**

Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006 website: www.clarislifesciences.com, e-mail: investorservices.corp@clarislifesciences.com, CIN: L85110GJ1994PLC022543

Unaudited Financial Results for the Quarter ended March 31, 2014

(Rs. In Lacs except EPS and Shares)

	Consolidated				(Hs. In Lacs except EPS and Shares)			
Particulars					Standalone Quarter Ended			V
		Quarter Ended		Year ended		Quarter Ended		Year ended
	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
PART I								
1. Income from Operations								
a. Net Sales/Income from Operations	13,309.17	14,442.59	18,216.54	65,837.55	12,497.77	14,356.40	15,562.67	62,879.35
( Net of excise duty )								
b. Other Operating Income	372.97	392.59	68.83	938.65	372.97	392.59	68.83	938.65
Total Income from operations ( net )	13,682.14	14,835.18	18,285.37	66,776.20	12,870.74	14,748.99	15,631.50	63,818.00
2. Expenses								
a. Cost of materials consumed	1,766.73	2,541.34	4,268.15	15,091.00	1,766.73	2,541.34	4,268.15	15,091.00
b. Purchase of stock-in- trade	6,725.96	5,733.86	1,011.40	9,095.54	6,137.89	5,568.22	765.05	9,378.23
c. Changes in inventories of finished goods,	(970.61)	(227.64)	1,055.92	518.89	(663.31)	83.58	492.89	(142.73)
work-in-progress and stock-in-trade								
d. Employee benefits expense	1,058.51	1,068.32	1,406.44	5,097.56	954.87	955.63	1,330.42	4,724.87
e. Depreciation and amortisation expense	1,018.44	1,034.87	2,157.65	6,535.38	824.27	839.63	1,985.44	5,796.11
f. Other expenses	3,200.68	3,870.08	5,885.20	20,034.56	2,745.94	3,815.20	5,598.21	18,995.05
Total Expenses	12,799.71	14,020.83	15,784.76	56,372.93	11,766.39	13,803.60	14,440.16	53,842.53
3. Profit / (Loss) from Operations before Other Income, finance costs	882.43	814.35	2,500.61	10,403.27	1,104.35	945.39	1,191.34	9,975.47
and exceptional Items (1-2)								
4. Other Income	1,911.34	1,917.60	749.15	4,058.75	1,799.26	1,932.64	646.71	4,049.53
5. Profit / (Loss) from ordinary activities before finance costs and	2,793.77	2,731.95	3,249.76	14,462.02	2,903.61	2,878.03	1,838.05	14,025.00
exceptional Items (3+4)								
6. Finance Costs	874.01	773.81	1,540.68	5,219.45	871.32	778.40	1,539.17	5,210.12
7. Profit / (Loss) from ordinary activities after finance costs but before	1,919.76	1,958.14	1,709.08	9,242.57	2,032.29	2,099.63	298.88	8,814.88
exceptional Items (5-6)								
8. Exceptional Items [ Income / ( Expense ) ]	-	-	-	1,505.98	-	-	-	1,505.98
9. Profit / (Loss) from Ordinary Activities before tax (7+8)	1,919.76	1,958.14	1,709.08	10,748.55	2,032.29	2,099.63	298.88	10,320.86
10. Tax Expense	378.50	101.33	159.85	2,207.71	375.19	94.54	159.85	2,199.01
11. Net Profit / (Loss) from Ordinary Activities after tax (9-10)	1,541.26	1,856.81	1,549.23	8,540.84	1,657.10	2,005.09	139.03	8,121.85
12. Extraordinary Item	-	-	-	1	i	-	-	-
13. Net Profit / (Loss) for the period (11-12)	1,541.26	1,856.81	1,549.23	8,540.84	1,657.10	2,005.09	139.03	8,121.85
14. Share in Profit/(Loss) from Associate	(206.88)	(81.60)	_	(99.87)	-	-	-	-
15. Minority interest	-	-	-	-	-	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit /	1,334.38	1,775.21	1,549.23	8,440.97	1,657.10	2,005.09	139.03	8,121.85
(loss) of associates (13+14+15)	,	,	•	,	,	•		,
17. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78	6,381.78
18. Reserve excluding Revaluation Reserves (As per Balance Sheet of	-	-	-	134,047.69	-	-	-	88,631.40
previous accounting year)				·				
19. Basic and Diluted Earnings Per Share (EPS) (before & after	2.09	2.78	2.43	13.23	2.60	3.14	0.22	12.73
extraordinary items ) ( of Rs. 10/- each ) (Not Annualised)		•	2	3.20		3	J.==	
, , , , , , , , , , , , , , , , , , , ,								
See accompanying note to the financial results								

## **Claris Lifesciences Limited**

Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006 website: www.clarislifesciences.com, e-mail: investorservices.corp@clarislifesciences.com, CIN: L85110GJ1994PLC022543

Unaudited Financial Results for the Quarter ended March 31, 2014

(Rs. In Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended			Year ended	Quarter Ended			Year ended
	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013	31st Mar 2014	31st Dec 2013	31st Mar 2013	31st Dec 2013
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
PART II								
A PARTICULARS OF SHAREHOLDING								
1. Public Shareholding								
- No. of shares	25,392,554	25,392,554	24,212,434	25,392,554	25,392,554	25,392,554	24,212,434	25,392,554
- Percentage of shareholding	39.79	39.79	37.94	39.79	39.79	39.79	37.94	39.79
2. Promoters and Promoter group shareholding								
a) Pledged/Encumbered								
- Number of shares	6,844,532	-	7,724,000	-	6,844,532	-	7,724,000	-
- Percentage of shares (as a % of the total shareholding of promoter and	17.81	-	19.50	-	17.81	-	19.50	-
promoter group)								
- Percentage of shares (as a% of the total share capital of the Company)	10.73	-	12.10	-	10.73	-	12.10	-
b) Non-encumbered								
- Number of Shares	31,580,679	38,425,211	31,881,331	38,425,211	31,580,679	38,425,211	31,881,331	38,425,211
- Percentage of shares (as a% of the total shareholding of promoter and	82.19	100.00	80.50	100.00	82.19	100.00	80.50	100.00
promoter group)								
- Percentage of shares (as a % of the total share capital of the Company)	49.49	60.21	49.96	60.21	49.49	60.21	49.96	60.21
B INVESTOR COMPLAINTS								
Pending at the beginning of the quarter	Nil							
Received during the quarter	3							
Disposed of during the quarter	3							
Remaining unresolved at the end of the quarter	Nil							

## Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9th May, 2014
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 On 31st July 2013, pursuant to agreements with Otsuka Pharmaceutical Factory, Inc., Japan (Otsuka) and Mitsui & Co. Ltd., Japan (Mitsui), the Company has transferred its Infusion Business to Claris Otsuka Limited on a slump sale basis. Post transfer of business, the Company holds 20% of equity share capital of Claris Otsuka Limited

Necessary disclosures pertaining to the discontinuing operations and re-organisation of the business, as per the requirements of Accounting Standard – 24 (AS-24) "Discontinuing Operations" are as under: -

(Rs. In Lacs)

	Consolidated and Standalone Results						
	Quarter Ended Y						
Particulars	31st March 2014	31st December 2013	31st March 2013	31st December 2013			
Revenue	-	-	8,235.00	22,055.73			
Profit / (Loss) Before Tax	-	-	1,104.66	2,958.61			
Profit / (Loss) After Tax	-	-	774.41	2,074.10			

In view of the transfer of the infusion business on 31st July, 2013, the figures for the quarters ended on 31st March 2014 and on 31st December 2013 do not include corresponding figures pertaining to the discontinued operations for respective periods and hence, to that extent, the same are not comparable with the figures for the previous corresponding periods / year.

4 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Limited

Place : Ahmedabad Date 9th May , 2014 Arjun Handa

Managing Director & CEO